Blueprint Medicines anticipates $360M-$390M in global AYVAKIT net product revenues for all approved indications in 2024. The midpoint of this range represents more than 80% year-over-year revenue growth, the majority of which is expected to be driven by ISM. The company continues to expect that operating expenses and cash burn will further decline in 2024, and that its existing cash, cash equivalents and investments, together with anticipated future product revenues, will maintain a durable capital position to enable the company to achieve a self-sustainable financial profile.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BPMC:
- Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
- Blueprint Medicines price target raised to $70 from $58 at Barclays
- BPMC Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Blueprint Medicines price target raised to $90 from $85 at Oppenheimer
- Blueprint Medicines price target raised to $78 from $58 at Piper Sandler
